Acne VulgarisPhase 1NCT01984801
Study to Investigate the Irritation Potential of GSK1940029 Gel
A Phase 1 study testing 0.3% GSK1940029 gel, 1% GSK1940029 gel and Sterile distilled water in people with Acne Vulgaris, run by GlaxoSmithKline at 1 site in Australia.
Trial summary
The proposed indication for GSK1940029 is topical treatment of acne, the early clinical plan will evaluate the irritation potential of GSK1940029 (Study SCD117225 - 3 Part study); and safety, tolerability and pharmacokinetics of GSK1940029 (Study SCD117226 - 2 Part study), after topical administration on healthy… Read more about this study
- Who is it for?
- Ages 18 to 65 yearsHealthy volunteers can take part
- Conditions the study is for
- Acne Vulgaris
- What is being tested?
- 0.3% GSK1940029 gel, 1% GSK1940029 gel and Sterile distilled water
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 54 participants
- Where
- 1 siteAustralia
- Study dates
- 14 Oct 2013to 10 Apr 2015
- Phase
- Phase 1
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 65 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Male or female between 18 and 65 years of age inclusive, at the time of signing the informed consent.
- Healthy as determined by a responsible and experienced physician, based on a medical evaluation including medical history, physical examination, laboratory tests and cardiac monitoring for Parts 1 and 2 only.
- Moderate/Moderate to Severe acne patients, otherwise healthy as determined by a responsible and experienced physician, based on a medical evaluation including medical history, physical examination, laboratory tests and cardiac monitoring for Part 3 only.
- A subject with a clinical abnormality or laboratory parameters outside the reference range for the population being studied may be included only if the Investigator and the GlaxoSmithKline (GSK) Medical Monitor agree that the finding is unlikely to introduce additional risk factors and will not interfere with the study procedures.
- A female subject is eligible to participate if she is of: Non-childbearing potential defined as pre-menopausal females with a documented tubal ligation or hysterectomy [for this definition, "documented" refers to the outcome of the investigator's/designee's review of the subject's medical history for study eligibility, as obtained via a verbal interview with the subject or from the subject's medical records]; or postmenopausal defined as 12 months of spontaneous amenorrhea [in questionable cases a blood sample with simultaneous follicle stimulating hormone (FSH) > 40 milli international units (MIU)/millilitres (mL) and estradiol <40 picograms (pg)/mL (<147 picomoles [pmol]/liter [L]) is confirmatory]. Females on hormone replacement therapy (HRT) and whose menopausal status is in doubt will not be allowed.
- Male subjects with female partners of child-bearing potential must agree to use one of the contraception methods. This criterion must be followed from the time of the first dose of study medication until after study follow-up visit.
Show all 9Show fewer
- Alanine aminotransferase (ALT), alkaline phosphatase and bilirubin <=1.5x upper limit of normal (ULN) (isolated bilirubin >1.5xULN is acceptable if bilirubin is fractionated and direct bilirubin <35%).
- Based on single or averaged assessments, QT duration corrected for heart rate (QTc) <450 msec; or QTc <480 msec in subjects with bundle branch block.
- Capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the consent form
Who cannot join
- A positive pre-study Hepatitis B surface antigen or positive Hepatitis C antibody result within 3 months of screening
- Current or chronic history of liver disease, or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome for all study Parts and asymptomatic gallstones for Parts 1 and 2 only). Subjects with a history of gall stones, asymptomatic gallstones or cholecystectomy will be excluded.
- A positive pre-study drug/alcohol screen.
- A positive test for Human Immunodeficiency Virus (HIV) antibody.
- History of regular alcohol consumption within 6 months of the study defined as: an average weekly intake of >14 standard drinks. One standard drink is equivalent to 10 grams (g) of alcohol: 285 mL of beer, 100 mL of wine or 30 mL of 40% alcohol by volume distilled spirits.
- History of or current meibomian gland dysfunction or dry eye disease
Show all 23Show fewer
- History or presence of significant skin disorder (such as but not limited to severe (extensive) atopic dermatitis, severe eczema, psoriasis or skin cancer) that would in any way confound interpretation of the study results, or subjects who present with damaged skin including sunburn, moles, uneven skin tones, scar tissue, tattoos, body piercings, sunburn, branding or other disfiguration on or near the intended site of application which could interfere with the grading. Acne is allowed for Part 3.
- History of cutaneous photodisorder, such as photoallergic reaction or polymorphic light eruption. History of cold urticaria and reactions to extreme temperatures.
- History of allergy to soaps, lotions, cosmetics, tape/adhesives, petrolatum or latex or topical drugs of same class as the study medication.
- History of sensitivity to any of the study medications, or components thereof or a history of drug or other allergy that, in the opinion of the investigator or GSK Medical Monitor, contraindicates their participation.
- History of sensitivity to heparin or heparin-induced thrombocytopenia.
- History of severe, chronic asthma or significant allergies (including food, drug or cutaneous allergies). Subjects with the presence or a history of atopy (seasonal allergies, allergic rhinitis) or mild (limited) eczema will be allowed to participate in the study, although applications at sites with active eczema will not be allowed.
- Use of topical medications such as but not limited to retinoids, steroids, and transdermal hormone replacement therapies on or near the intended site of application within 8 weeks prior to dosing through treatment follow up, for Parts 1 and 2 only or within 2 weeks period to dosing for Part 3. Use of other topical preparations such as those containing vitamins, supplements or herbal within 2 weeks prior to dosing through treatment follow up.
- Unable to refrain from the use of topical medications from the initial dose of study medication through follow-up.
- Foreseeable intensive Ultraviolet (UV) exposure during the study (solar or artificial) as follows: subjects must not be exposed to direct sunlight for sun tanning or exposed to skin tanning devices (e.g. sunbed) for the duration of the study.
- Participation in any patch test for cumulative irritation or sensitization within 4 weeks preceding the first dose of study medication.
- Exposure to more than four new chemical entities within 12 months prior to the first dosing day.
- The subject has participated in a clinical trial and has received an investigational product within the following time period prior to the first dosing day in the current study: 30 days, 5 half-lives or twice the duration of the biological effect of the investigational product (whichever is longer).
- Unable to refrain from the use of prescription or non-prescription drugs, including vitamins, herbal and dietary supplements (including St John's Wort) within 7 days (or 14 days if the drug is a potential enzyme inducer) or 5 half-lives (whichever is longer) prior to the first dose of study medication, unless in the opinion of the Investigator and GSK Medical Monitor the medication will not interfere with the study procedures or compromise subject safety.
- Where participation in the study would result in donation of blood or blood products in excess of 500 mL within a 56 day period.
- Unwillingness or inability to follow the procedures outlined in the protocol.
- Subject is mentally or legally incapacitated.
- Unable to refrain from consumption of red wine, seville oranges, grapefruit or grapefruit juice and/or pummelos, exotic citrus fruits, grapefruit hybrids or fruit juices from 7 days prior to the first dose of study medication
Trial locations and contacts
1 site in 1 country.
About this study
Official title: A Single-Blind Study to Evaluate the Irritation Potential of Repeat Topical Applications of GSK1940029 Gel on the Intact Skin of Healthy Human Subjects and Acne Patients
The proposed indication for GSK1940029 is topical treatment of acne, the early clinical plan will evaluate the irritation potential of GSK1940029 (Study SCD117225 - 3 Part study); and safety, tolerability and pharmacokinetics of GSK1940029 (Study SCD117226 - 2 Part study), after topical administration on healthy subjects and acne patients. Study SCD117225 will be a randomized, single-blind, three part study, to evaluate the primary irritation potential (Part 1), cumulative irritation potential (Part 2) of two concentrations of GSK1940029 gel applied to the intact skin of healthy subjects, and the facial irritation potential of one or two concentrations of GSK1940029 applied to the face of acne patients (Part3). In Part 1 and Part 2 the following 6 treatments will be applied using individual patches: (A) 200 milligrams (mg) of 0.3% GSK1940029 gel, (B) 200 mg of 1% GSK1940029 gel, (C) 200 mg of 0.3%/1% vehicle gel only (vehicle control), (D) 200 microliters (µL) of sterile distilled water (negative irritant control), (E) 200 µL of - 0.5% sodium lauryl sulfate (SLS) in sterile distilled water for Part 1/0.1% SLS in sterile distilled water for Part 2 (positive irritant control), and (F) Patch only (patch control). Each treatment will be randomized to one of six designated locations on either upper arm or other locations, such as the lower or upper back, within each subject. The same treatment will be reapplied to the same location on subsequent days. Each treatment will be applied daily for 2 days in Part 1, and daily for 21 days in Part 2. In Part 3, each patient will apply a thin coat of one or two concentration of GSK1940029 gel or vehicle to acne affected facial/neck skin by hand, once daily for 28 days. Parts within Study SCD117225 and Study SCD117226 will have interdependencies. No significant primary irritation signal in Study SCD117225 Part 1 would allow initiation of Study SCD117226 Part 1 (single dose application). Once safety, tolerability and exposure information are determined in Study SCD117226 Part 1, Part 2 of Study SCD117225 may be initiated along with Part 2 (14-day repeat dose application). No significant cumulative irritation signal (study SCD117225 Part 2) in combination with adequate 14-day safety (study SCD117226 Part 2) would allow initiation of Part 3 of Study SCD117225.
- Conditions
- Acne Vulgaris
- Being tested
- 0.3% GSK1940029 gel, 1% GSK1940029 gel, 0.3%/1% vehicle gel only, Sterile distilled water, 0.5% SLS in sterile distilled water
- Keywords
- SCD1, Gel, Topical Administration, Acne
- Medical subject headings
- Acne Vulgaris
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
0.3% GSK1940029 gelDrug
200 mg of the gel will be applied to individual patches by using a spatula
1% GSK1940029 gelDrug
200 mg of the gel will be applied to individual patches by using a spatula
0.3%/1% vehicle gel onlyDrug
200 mg of the gel will be applied to individual patches by using a spatula
Sterile distilled waterOther
200 µL of the solution will be applied to individual patches by using a pipette or syringe
0.5% SLS in sterile distilled waterOther
200 µL of the solution will be applied to individual patches by using a pipette or syringe
0.1% SLS in sterile distilled waterOther
200 µL of the solution will be applied to individual patches by using a pipette or syringe
Patch onlyOther
Only patch will be applied
| Study group | Role | What they receive |
|---|---|---|
| Part 1 | Experimental | Each of the following 6 treatments will be randomized to one of 6 designated locations on either upper arm or other locations, such as the lower or upper back, within each healthy subject: (A) 200 mg of 0.3% GSK1940029 gel, (B) 200 mg of 1% GSK1940029 gel, (C) 200 mg of 0.3%/1% vehicle gel only, (D) 200 µL of sterile distilled water, (E) Patch only, and (F) 200 µL of 0.5% SLS in sterile distilled water, Each treatment will be applied using individual patches, daily for 2 days Receives: Drug: 0.3% GSK1940029 gel; Drug: 1% GSK1940029 gel; Drug: 0.3%/1% vehicle gel only; Other: Sterile distilled water; Other: 0.5% SLS in sterile distilled water; Other: Patch only |
| Part 2 | Experimental | Each of the following 6 treatments will be randomized to one of 6 designated locations on either upper arm or other locations, such as the lower or upper back, within each healthy subject: (A) 200 mg of 0.3% GSK1940029 gel, (B) 200 mg of 1% GSK1940029 gel, (C) 200 mg of 0.3%/1% vehicle gel only, (D) 200 µL of sterile distilled water, (E) Patch only, and (F) 200 µL of 0.1% SLS in sterile distilled water. Each treatment will be applied using individual patches, daily for 21 days Receives: Drug: 0.3% GSK1940029 gel; Drug: 1% GSK1940029 gel; Drug: 0.3%/1% vehicle gel only; Other: Sterile distilled water; Other: 0.1% SLS in sterile distilled water; Other: Patch only |
| Part 3 | Experimental | Each acne patient will apply a thin coat of one or two concentration of GSK1940029 gel or vehicle to acne affected facial/neck skin by hand, once daily for 28 days Receives: Drug: 0.3% GSK1940029 gel; Drug: 1% GSK1940029 gel; Drug: 0.3%/1% vehicle gel only |
What is being measured
The primary outcome is the main question the study is designed to answer.
Primary cutaneous irritation scores
The patch/test sites will be evaluated for irritation potential and will be graded using a grading scale based on scales developed by Hill Top Research, Inc and cited by the United States (US) Food and Drug Administration (FDA) in the Draft Guidance for Industry: Skin Irritation and Sensitization Testing of Generic Transdermal Drug Products, December 1999
Measured: Days 2, 3 4 and 5 of Part 1
Cumulative cutaneous irritation scores
Visual evaluations of the patch/test sites will be performed for irritation potential approximately 24 hours after each patch application, and will be graded using a grading scale based on scales developed by Hill Top Research, Inc and cited by the US FDA in the Draft Guidance for Industry: Skin Irritation and Sensitization Testing of Generic Transdermal Drug Products, December 1999
Measured: Day 2 to Day 22 of Part 2
Facial irritation scores
The Facial Irritation Scoring System will be based on the Draize Scoring System with an additional Sensation of Burning/Stinging category
Measured: Days 1, 7, 14, 21, 28, 29 and at FU (Days 35-42) of Part 3
Lanman-Maibach irritation classifications
The derived cumulative irritation scores will be interpreted using the Lanman-Maibach classification system
Measured: Day 2 to Day 22 of Part 2
Tolerability of GSK1940029 as assessed by Clinical monitoring/observation
Measured: Up to Day 17 of Part 1, Up to Day 36 of Part 2, and Up to Day 42 of Part 3
Tolerability of GSK1940029 as assessed by adverse events (AEs)
Measured: Up to Day 17 of Part 1, Up to Day 36 of Part 2, and Up to Day 42 of Part 3
Secondary outcomes (5)
Safety and tolerability of GSK1940029 as assessed by clinical laboratory tests
Clinical laboratory tests will include hematology, chemistry and urinalysis parameters
Measured: Screening, Days 1, 4, and FU (Days 10 to 17) of Part 1. Screening, Days 1, 8, 22, and FU (Days 29 to 36) of Part 2. Screening, Days 1, 7, 14, 21, 29, and FU (Days 35 to 42) of Part 3.
Safety and tolerability of GSK1940029 as assessed by vital signs measurements
Vital signs measurements will include systolic and diastolic blood pressure and heart rate
Measured: Screening, Days 1, 2, and FU (Days 10 to 17) of Part 1. Screening, Days 1, 2 and FU (Days 29 to 36) of Part 2. Screening, Days 1, 2 and FU (Days 35 to 42) of Part 3
Safety and tolerability of GSK1940029 as assessed by clinical monitoring/observation
Measured: Up to Day 17 of Part 1, Up to Day 36 of Part 2, and Up to Day 42 of Part 3
Ocular tolerability of topical applications of GSK1940029
Eye examination will be performed. Ocular evaluations will include slit lamp examination with fluorscein, tear film breakup time, visual acuity and ocular surface disease index
Measured: Screening, Days 1, 5, and FU (Days 10 to 17) of Part 1. Screening, Days 1, 22, and FU (Days 29 to 36) of Part 2. Screening, Days 1, 7, 14, 21, 29, and FU (Days 35 to 42) of Part 3.
Plasma GSK1940029 pharmacokinetics (PK)
Blood samples for PK analysis of GSK1940029 will be collected. PK parameters will include Area under the concentration-time curve: from time zero (pre-dose) to last time of quantifiable concentration within a subject across all treatments [AUC(0-t)] and from time zero (pre-dose) extrapolated to infinite time [AUC(0-infinity)]; maximum observed concentration (Cmax); time of occurrence of cmax (tmax); and terminal phase half-life (t1/2) as data permit
Measured: Part 3 Only - Days 1 and 28: pre-dose, 2, 4, and 8 hours post-dose; Day 2: pre-dose; and Day 29: 24 hour post-Day 28 dose
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted15 Nov 2013 (estimated)
- Study start14 Oct 2013
- Primary completion10 Apr 2015
- Study completion10 Apr 2015
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Acne VulgarisStudies of the same condition, open and under way.
- More trials run by GlaxoSmithKlineThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Single group
- Masking
- Single blind
- Who is masked
- Participant
- Enrolment
- 54 participants (actual)
Sponsor and investigators
- Lead sponsor
- GlaxoSmithKline
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- GSK Clinical Trials, Study director, GlaxoSmithKline
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01984801
- Sponsor's protocol ID
- 117225
- Status last verified
- May 2017
- First submitted
- 5 Sep 2013
- Last updated
- 9 May 2017
- Results posted
- No
- Data monitoring committee
- No
Study at a glance
From the registry record, last updated by the sponsor on 9 May 2017. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Single-Blind Study to Evaluate the Irritation Potential of Repeat Topical Applications of GSK1940029 Gel on the Intact Skin of Healthy Human Subjects and Acne Patients
- ClinicalTrials.gov ID
- NCT01984801
- Acronym / sponsor ID
- 117225
- Conditions
- Acne Vulgaris
- Keywords
- SCD1, Gel, Topical Administration, Acne
- Phase
- Phase 1
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 54 participants (actual)
- Lead sponsor
- GlaxoSmithKlineIndustry (pharma, biotech, devices)
- Study start
- 14 Oct 2013 (actual)
- Primary completion
- 10 Apr 2015 (actual)
- Study completion
- 10 Apr 2015 (actual)
- First posted
- 15 Nov 2013 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The proposed indication for GSK1940029 is topical treatment of acne, the early clinical plan will evaluate the irritation potential of GSK1940029 (Study SCD117225 - 3 Part study); and safety, tolerability and pharmacokinetics of GSK1940029 (Study SCD117226 - 2 Part study), after topical administration on healthy subjects and acne patients. Study SCD117225 will be a randomized, single-blind, three part study, to evaluate the primary irritation potential (Part 1), cumulative irritation potential (Part 2) of two concentrations of GSK1940029 gel applied to the intact skin of healthy subjects, and the facial irritation potential of one or two concentrations of GSK1940029 applied to the face of acne patients (Part3). In Part 1 and Part 2 the following 6 treatments will be applied using individual patches: (A) 200 milligrams (mg) of 0.3% GSK1940029 gel, (B) 200 mg of 1% GSK1940029 gel, (C) 200 mg of 0.3%/1% vehicle gel only (vehicle control), (D) 200 microliters (µL) of sterile distilled water (negative irritant control), (E) 200 µL of - 0.5% sodium lauryl sulfate (SLS) in sterile distilled water for Part 1/0.1% SLS in sterile distilled water for Part 2 (positive irritant control), and (F) Patch only (patch control). Each treatment will be randomized to one of six designated locations on either upper arm or other locations, such as the lower or upper back, within each subject. The same treatment will be reapplied to the same location on subsequent days. Each treatment will be applied daily for 2 days in Part 1, and daily for 21 days in Part 2. In Part 3, each patient will apply a thin coat of one or two concentration of GSK1940029 gel or vehicle to acne affected facial/neck skin by hand, once daily for 28 days. Parts within Study SCD117225 and Study SCD117226 will have interdependencies. No significant primary irritation signal in Study SCD117225 Part 1 would allow initiation of Study SCD117226 Part 1 (single dose application). Once safety, tolerability and exposure information are determined in Study SCD117226 Part 1, Part 2 of Study SCD117225 may be initiated along with Part 2 (14-day repeat dose application). No significant cumulative irritation signal (study SCD117225 Part 2) in combination with adequate 14-day safety (study SCD117226 Part 2) would allow initiation of Part 3 of Study SCD117225.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Single group
- Masking
- Single blind (participant)
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| Part 1 | Experimental | Drug: 0.3% GSK1940029 gel, Drug: 1% GSK1940029 gel, Drug: 0.3%/1% vehicle gel only, Other: Sterile distilled water, Other: 0.5% SLS in sterile distilled water, Other: Patch onlyEach of the following 6 treatments will be randomized to one of 6 designated locations on either upper arm or other locations, such as the lower or upper back, within each healthy subject: (A) 200 mg of 0.3% GSK1940029 gel, (B) 200 mg of 1% GSK1940029 gel, (C) 200 mg of 0.3%/1% vehicle gel only, (D) 200 µL of sterile distilled water, (E) Patch only, and (F) 200 µL of 0.5% SLS in sterile distilled water, Each treatment will be applied using individual patches, daily for 2 days |
| Part 2 | Experimental | Drug: 0.3% GSK1940029 gel, Drug: 1% GSK1940029 gel, Drug: 0.3%/1% vehicle gel only, Other: Sterile distilled water, Other: 0.1% SLS in sterile distilled water, Other: Patch onlyEach of the following 6 treatments will be randomized to one of 6 designated locations on either upper arm or other locations, such as the lower or upper back, within each healthy subject: (A) 200 mg of 0.3% GSK1940029 gel, (B) 200 mg of 1% GSK1940029 gel, (C) 200 mg of 0.3%/1% vehicle gel only, (D) 200 µL of sterile distilled water, (E) Patch only, and (F) 200 µL of 0.1% SLS in sterile distilled water. Each treatment will be applied using individual patches, daily for 21 days |
| Part 3 | Experimental | Drug: 0.3% GSK1940029 gel, Drug: 1% GSK1940029 gel, Drug: 0.3%/1% vehicle gel onlyEach acne patient will apply a thin coat of one or two concentration of GSK1940029 gel or vehicle to acne affected facial/neck skin by hand, once daily for 28 days |
Who may qualify
- Ages
- 18 to 65 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (9 listed)
- Male or female between 18 and 65 years of age inclusive, at the time of signing the informed consent.
- Healthy as determined by a responsible and experienced physician, based on a medical evaluation including medical history, physical examination, laboratory tests and cardiac monitoring for Parts 1 and 2 only.
- Moderate/Moderate to Severe acne patients, otherwise healthy as determined by a responsible and experienced physician, based on a medical evaluation including medical history, physical examination, laboratory tests and cardiac monitoring for Part 3 only.
- A subject with a clinical abnormality or laboratory parameters outside the reference range for the population being studied may be included only if the Investigator and the GlaxoSmithKline (GSK) Medical Monitor agree that the finding is unlikely to introduce additional risk factors and will not interfere with the study procedures.
- A female subject is eligible to participate if she is of: Non-childbearing potential defined as pre-menopausal females with a documented tubal ligation or hysterectomy [for this definition, "documented" refers to the outcome of the investigator's/designee's review of the subject's medical history for study eligibility, as obtained via a verbal interview with the subject or from the subject's medical records]; or postmenopausal defined as 12 months of spontaneous amenorrhea [in questionable cases a blood sample with simultaneous follicle stimulating hormone (FSH) > 40 milli international units (MIU)/millilitres (mL) and estradiol <40 picograms (pg)/mL (<147 picomoles [pmol]/liter [L]) is confirmatory]. Females on hormone replacement therapy (HRT) and whose menopausal status is in doubt will not be allowed.
Key exclusion criteria (23 listed)
- A positive pre-study Hepatitis B surface antigen or positive Hepatitis C antibody result within 3 months of screening
- Current or chronic history of liver disease, or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome for all study Parts and asymptomatic gallstones for Parts 1 and 2 only). Subjects with a history of gall stones, asymptomatic gallstones or cholecystectomy will be excluded.
- A positive pre-study drug/alcohol screen.
- A positive test for Human Immunodeficiency Virus (HIV) antibody.
- History of regular alcohol consumption within 6 months of the study defined as: an average weekly intake of >14 standard drinks. One standard drink is equivalent to 10 grams (g) of alcohol: 285 mL of beer, 100 mL of wine or 30 mL of 40% alcohol by volume distilled spirits.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| 0.3% GSK1940029 gel200 mg of the gel will be applied to individual patches by using a spatula | Drug | Part 1, Part 2, Part 3 |
| 1% GSK1940029 gel200 mg of the gel will be applied to individual patches by using a spatula | Drug | Part 1, Part 2, Part 3 |
| 0.3%/1% vehicle gel only200 mg of the gel will be applied to individual patches by using a spatula | Drug | Part 1, Part 2, Part 3 |
| Sterile distilled water200 µL of the solution will be applied to individual patches by using a pipette or syringe | Other | Part 1, Part 2 |
| 0.5% SLS in sterile distilled water200 µL of the solution will be applied to individual patches by using a pipette or syringe | Other | Part 1 |
| 0.1% SLS in sterile distilled water200 µL of the solution will be applied to individual patches by using a pipette or syringe | Other | Part 2 |
| Patch onlyOnly patch will be applied | Other | Part 1, Part 2 |
Primary outcome
Primary cutaneous irritation scores
Time frame: Days 2, 3 4 and 5 of Part 1
The patch/test sites will be evaluated for irritation potential and will be graded using a grading scale based on scales developed by Hill Top Research, Inc and cited by the United States (US) Food and Drug Administration (FDA) in the Draft Guidance for Industry: Skin Irritation and Sensitization Testing of Generic Transdermal Drug Products, December 1999
Cumulative cutaneous irritation scores
Time frame: Day 2 to Day 22 of Part 2
Visual evaluations of the patch/test sites will be performed for irritation potential approximately 24 hours after each patch application, and will be graded using a grading scale based on scales developed by Hill Top Research, Inc and cited by the US FDA in the Draft Guidance for Industry: Skin Irritation and Sensitization Testing of Generic Transdermal Drug Products, December 1999
Facial irritation scores
Time frame: Days 1, 7, 14, 21, 28, 29 and at FU (Days 35-42) of Part 3
The Facial Irritation Scoring System will be based on the Draize Scoring System with an additional Sensation of Burning/Stinging category
Lanman-Maibach irritation classifications
Time frame: Day 2 to Day 22 of Part 2
The derived cumulative irritation scores will be interpreted using the Lanman-Maibach classification system
Tolerability of GSK1940029 as assessed by Clinical monitoring/observation
Time frame: Up to Day 17 of Part 1, Up to Day 36 of Part 2, and Up to Day 42 of Part 3
Tolerability of GSK1940029 as assessed by adverse events (AEs)
Time frame: Up to Day 17 of Part 1, Up to Day 36 of Part 2, and Up to Day 42 of Part 3
5 secondary outcomes
Safety and tolerability of GSK1940029 as assessed by clinical laboratory tests
Time frame: Screening, Days 1, 4, and FU (Days 10 to 17) of Part 1. Screening, Days 1, 8, 22, and FU (Days 29 to 36) of Part 2. Screening, Days 1, 7, 14, 21, 29, and FU (Days 35 to 42) of Part 3.
Safety and tolerability of GSK1940029 as assessed by vital signs measurements
Time frame: Screening, Days 1, 2, and FU (Days 10 to 17) of Part 1. Screening, Days 1, 2 and FU (Days 29 to 36) of Part 2. Screening, Days 1, 2 and FU (Days 35 to 42) of Part 3
Safety and tolerability of GSK1940029 as assessed by clinical monitoring/observation
Time frame: Up to Day 17 of Part 1, Up to Day 36 of Part 2, and Up to Day 42 of Part 3
Ocular tolerability of topical applications of GSK1940029
Time frame: Screening, Days 1, 5, and FU (Days 10 to 17) of Part 1. Screening, Days 1, 22, and FU (Days 29 to 36) of Part 2. Screening, Days 1, 7, 14, 21, 29, and FU (Days 35 to 42) of Part 3.
Plasma GSK1940029 pharmacokinetics (PK)
Time frame: Part 3 Only - Days 1 and 28: pre-dose, 2, 4, and 8 hours post-dose; Day 2: pre-dose; and Day 29: 24 hour post-Day 28 dose
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 9 May 2017.
- Results for study 117225 can be found on the GSK Clinical Study Register.Link provided by the sponsor.
Related trials for Acne Vulgaris
Not yet recruitingPhase 3
Evaluation of the Efficacy and Safety of Fractional CO₂ Laser With and Without Intradermal Botulinum Toxin A in the Treatment of Inflammatory Facial Acne Vulgaris.
Acne, Acne Papulopustulosa
RecruitingPhase 4
Safety, Tolerability, and Clinical Effectiveness of Adapalene/Clindamycin Phosphate Gel (Klenzit®-C) in Vietnamese Patients With Mild to Moderate Acne Vulgaris
Acne
RecruitingPhase 3
Phase 3 Study of Denifanstat in Participants With Moderate to Severe Acne (AURORA)
Acne Vulgaris
RecruitingPhase 4
Comparing Nadifloxacin Plus Tretinoin Versus Clindamycin Plus Tretinoin Creams for Mild-to-Moderate Acne
Acne Vulgaris
Active, not recruiting
Clinical Study to Evaluate the Safety and Efficacy of Candela Technology
Hair Reduction, Tattoo Removal
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
GSK Clinical Trials study director
GlaxoSmithKline
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 1 study testing 0.3% GSK1940029 gel, 1% GSK1940029 gel and Sterile distilled water in people with Acne Vulgaris, run by GlaxoSmithKline at 1 site in Australia.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 9 inclusion and 23 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 9 May 2017. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Australia. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Primary cutaneous irritation scores (time frame: Days 2, 3 4 and 5 of Part 1). The study lists 6 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 May 2017.